LoQus23 Therapeutics

About LoQus23 Therapeutics

LoQus23 Therapeutics is focused on developing small molecule somatic expansion inhibitors to treat Huntington's Disease and other triplet repeat expansion diseases, with the aim of stopping DNA instability and slowing neurodegenerative disease progression.

Products & Services

Small Molecule Somatic Expansion Inhibitors:Therapeutics designed for the treatment of Huntington's Disease and other triplet repeat expansion diseases, aiming to stop DNA instability and slow neurodegeneration.

Specialties

Small Molecule Therapeutics Neurodegenerative Disease Treatment Huntington's Disease Triplet Repeat Expansion Diseases DNA Instability Inhibition

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 43000000 MR: - FA: £35 million FAN: 43000000	D: 2024-10-02 FD: 2024-10-02	3 investors

Series A Latest

2024-10-02

$43.0M

3 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Cyrus Mozayeni

Chief Executive Officer of Pheon Therapeutics

C

Christian Jung

Partner at SV Health Investors

R

Rogier Rooswinkel

General Partner at the Naarden office

F

Florian Muellershausen

Managing Director

M

Melanie Ivarsson

Chief Development Officer at Moderna

D

David Reynolds

Chief Executive Officer

View 11 more team members with Pro

Unlock Full Team Directory

Recent News